Email updates

Keep up to date with the latest news and content from BMC Pulmonary Medicine and BioMed Central.

Open Access Research article

Is it possible to diagnose the therapeutic adherence of patients with COPD in clinical practice? A cohort study

Pilar Barnestein-Fonseca1*, José Leiva-Fernández2, Francisca Vidal-España3, Antonio García-Ruiz4, Daniel Prados-Torres5 and Francisca Leiva-Fernández6

Author Affiliations

1 Family and Community Medicine Teaching Unit of Malaga. Health District Malaga. Málaga, Spain

2 Vélez Sur Health Centre. Axarquía Health District. Vélez Málaga (Málaga), Spain

3 Sociologist. Family and Community Medicine Teaching Unit of Malaga. Health District Malaga. Málaga, Spain

4 Farmacoeconomy and SRI Unit. Farmacoeconomy and Clinical Therapeutic Department. Faculty of Medicine. Malaga University. Málaga, Spain

5 Family and Community Medicine Teaching Unit of Malaga. Health District Malaga. Málaga, Spain

6 Family and Community Medicine Teaching Unit of Malaga. Health District Malaga. Málaga, Spain

For all author emails, please log on.

BMC Pulmonary Medicine 2011, 11:6  doi:10.1186/1471-2466-11-6

Published: 24 January 2011

Abstract

Background

Therapeutic adherence of patients with chronic obstructive pulmonary disease (COPD) is poor. It is therefore necessary to determine the magnitude of non-adherence to develop strategies to correct this behaviour. The purpose of this study was to analyse the diagnostic validity of indirect adherence methods.

Methods

Sample: 195 COPD patients undergoing scheduled inhaled treatment attending 5 Primary Care Centres of Malaga, Spain. Variables: Sociodemographic profile, illness data, spirometry, quality of life (St. George Respiratory Questionnaire: SGRQ), and inhaled medication counting (count of dose/pill or electronic monitoring) were collected. The patient's knowledge of COPD (Batalla test:BT),their attitude towards treatment (Morisky-Green test: MGT) and their self-reported therapeutic adherence (Haynes-Sackett test: HST) were used as methods of evaluating adherence. The follow-up consisted four visits over one year (the recruitment visit: V0; and after 1 month:V1; 6 months:V2; and 1 year:V3).

Results

The mean age was 69.59 (95% CI, 68.29-70.89) years old and 93.8% were male. Other findings included: 85.4% had a low educational level, 23.6% were smokers, 71.5% mild-moderate COPD stage with a FEV1 = 56.86 (SD = 18.85); exacerbations per year = 1.41(95% CI, 1-1.8). The total SGRQ score was 44.96 (95% CI, 42.46-47.46), showing a mild self-perceived impairment in health. The prevalence of adherence (dose/pill count) was 68.1% (95% CI, 60.9-75.3) at V1, 80% (95% CI, 73-87) at V2 and 84% (95% CI, 77.9) at V3. The MGT showed a specificity of 67.34% at V1, 76.19% at V2 and 69.62% at V3. The sensitivity was 53.33% at V1, 66.66% at V2 and 33.33% at V3.The BT showed a specificity of 55.1% at V1, 70.23% at V2 and 67.09% at V3. The sensitivity was 68.88% at V1, 71.43% at V2 and 46.66% at V3. Considering both tests together, the specificity was 86.73% at V1, 94.04% at V2 and 92.49% at V3 and the sensitivity was 37.77% at V1, 47.62% at V2 and 13.3% at V3.

Conclusions

The prevalence of treatment adherence changes over time. Indirect methods (dose/pill count and self-reported) can be useful to detect non-adherence in COPD patients. The combination of MGT and BT is the best approach to test self-reported adherence.